<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE - neomycin sulfate, polymyxin b sulfate and hydrocortisone suspension </strong><br>STAT RX USA LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<br><a href="#section-"></a>DESCRIPTION<p class="First">Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic 
Suspension is a sterile antimicrobial and anti-inflammatory suspension for 
ophthalmic use.</p>
<p><span class="Bold">Each mL contains: Actives: </span>neomycin sulfate 
(equivalent to 3.5 mg neomycin base), polymyxin B sulfate equivalent to 10,000 
polymyxin B units, and hydrocortisone 10 mg (1%). <span class="Bold">Preservative: 
</span>thimerosal 0.001%. <span class="Bold">Inactives: </span>cetyl alcohol, 
glyceryl monostearate, mineral oil, polyoxyl 40 stearate, propylene glycol, 
sulfuric acid (to adjust pH) and water for injection.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced 
by the growth of <span class="Italics">Streptomyces fradiae </span>Waksman (Fam. 
Streptomycetacae). It has a potency equivalent to not less than 600 μg of 
neomycin standard per mg, calculated on an anhydrous basis. Its structural 
formula are:</p>
<p><img alt="neomycin-01 IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64e4cb91-f5bd-4a2f-b92d-0a1341f40d35&amp;name=neomycin-01.jpg">     neomycin-01 IMAGE</p>
<p>Polymyxin B sulfate is the sulfate salt of Polymyxin, B1 and B2, which are 
produced by the growth of <span class="Italics">Bacillus polymyxa 
</span>(Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 
6,000 polymyxin B units per mg calculated on an anhydrous basis. Its structural 
formula are:</p>
<p><img alt="neomycin-02 IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64e4cb91-f5bd-4a2f-b92d-0a1341f40d35&amp;name=neomycin-02.jpg">     neomycin-02 IMAGE</p>
<p>Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20 dione, is an 
anti-inflammatory hormone. Its structural formula is:</p>
<p> <img alt="neomycin-03 IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64e4cb91-f5bd-4a2f-b92d-0a1341f40d35&amp;name=neomycin-03.jpg">    neomycin-03 IMAGE<br></p>
<p><br></p>
<span class="Bold"><span class="Bold"></span></span>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<a href="http://"></a>CLINICAL PHARMACOLOGY<p class="First">Corticosteroids suppress the inflammatory response to a variety 
of agents, and they probably delay or slow healing. Since corticosteroids may 
inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, concomitant 
antimicrobial drugs may be used when this inhibition is considered to be 
clinically significant in a particular case.</p>
<p>When a decision to administer both a corticosteroid and antimicrobials is 
made, the administration of such drugs in combination has the advantage of 
greater patient compliance and convenience, with the added assurance that the 
intended dosage of all drugs is administered. When each type of drug is in the 
same formulation, compatibility of ingredients is assured and the correct volume 
of drug is delivered and retained.</p>
<p>The relative potency of corticosteroids depends on the molecular structure, 
concentration, and release from the vehicle.</p>
<p><span class="Bold">Microbiology: </span>The anti-infective components in 
Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension are 
included to provide action against specific organisms susceptible to it. 
Neomycin sulfate and polymyxin B sulfate are active <span class="Italics">in vitro 
</span>against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms: <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">Escherichia 
coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/Enterbacter </span>species, <span class="Italics">Neisseria </span>species, and <span class="Italics">Pseudomonas 
aeruginosa</span>. The product does not provide adequate coverage against <span class="Italics">Serratia marcescens </span>and streptococci, including <span class="Italics">Streptococcus pneumoniae </span>(see <span><a href="#splSectionIndicationsUsage">INDICATIONS AND USAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<a href="http://"></a>INDICATIONS AND USAGE<p class="First">Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic 
Suspension is indicated for steroid-responsive inflammatory ocular conditions 
for which a corticosteroid is indicated and where <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a risk 
of bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> exists.</p>
<p>Ocular corticosteroids are indicated in inflammatory conditions of the 
palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where 
the inherent risk of corticosteroid use in certain infective conjunctivitides is 
accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also 
indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, 
radiation, or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.</p>
<p>The use of a combination drug with an anti-infective component is indicated 
where the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that 
potentially dangerous numbers of bacteria will be present in the eye (See <span><a href="#splSectionClinicalPharmacology">CLINICAL 
PHARMACOLOGY: Microbiology</a></span>).</p>
<p>The particular anti-infective drugs in this product are active against the 
following common bacterial eye pathogens: <span class="Italics">Staphylococcus 
aureus</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/Enterobacter </span>species, <span class="Italics">Neisseria </span>species, and <span class="Italics">Pseudomonas 
aeruginosa</span>.</p>
<p>The product does not provide adequate coverage against <span class="Italics">Serratia marcescens </span>and streptococci, including <span class="Italics">Streptococcus pneumoniae</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<a href="http://"></a>CONTRAINDICATIONS<p class="First">Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic 
Suspension is contraindicated in most viral diseases of the cornea and 
conjunctiva including: epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (dendritic 
<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the 
eye and fungal diseases of ocular structures.</p>
<p>Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is 
also contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of 
its components. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the antibiotic component occurs at a higher 
rate than for other components.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<a href="http://"></a>WARNINGS<p class="First">NOT FOR INJECTION INTO THE EYE. Neomycin and Polymyxin B Sulfates 
and Hydrocortisone Ophthalmic Suspension should never be directly introduced 
into the anterior chamber of the eye.</p>
<p>Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and/or 
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of 
vision, and <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation.</p>
<p>Prolonged use may suppress the host response and thus increase the hazard of 
secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In those diseases causing thinning of the cornea or 
sclera, perforations have been known to occur with the use of topical 
corticosteroids. In acute purulent conditions of the eye, corticosteroids may 
mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>If these products are used for 10 days or longer, intraocular pressure should 
be routinely monitored even though it may be difficult in uncooperative 
patients. Corticosteroids should be used with caution in the presence of 
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>The use of corticosteroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and 
increase the incidence of filtering blebs.</p>
<p>Use of ocular corticosteroids may prolong the course and may exacerbate the 
severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). 
Employment of corticosteroid medication in the treatment of herpes simplex 
requires great caution.</p>
<p>Topical antibiotics, particularly, neomycin sulfate, may cause cutaneous 
sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily skin 
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>) due to topical antibiotics is not known. The manifestations of 
sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> 
of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a 
failure to heal. During long-term use of topical antibiotic products, periodic 
examination for such signs is advisable, and the patient should be told to 
discontinue the product if they are observed. Symptoms usually subside quickly 
on withdrawing the medication. Application of products containing these 
ingredients should be avoided for the patient thereafter (see <span><a href="#splSectionPrecautionsGeneral">PRECAUTIONS: 
General</a></span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>PRECAUTIONS<a href="http://"></a><a href="http://"></a><a href="http://"></a>General<p>The initial prescription and renewal of the medication order 
beyond 20 mL should be made by a physician only after examination of the patient 
with the aid of magnification, such as slit lamp biomicroscopy and, where 
appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 
days, the patient should be re-evaluated.</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after 
prolonged corticosteroid dosing. Fungal cultures should be taken when 
appropriate.</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be 
monitored (see <span><a href="#splSectionWarnings">WARNINGS</a></span>).</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of 
topical ophthalmic products in multiple-dose containers which have been 
inadvertently contaminated by patients, most of whom had a concurrent corneal 
disease or a disruption of the ocular epithelial surface (see <span><a href="#splSectionPrecautionsPatientInfo">PRECAUTIONS: 
Information for Patients</a></span>).</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all 
of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: kanamycin, 
paromomycin, streptomycin, and possibly gentamicin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6"></a><p></p>
<a href="#section-"></a>Information for Patients<p class="First">Patients should be instructed to avoid allowing the tip of the 
dispensing container to contact the eye, eyelid, fingers, or any other surface. 
The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Patients should also be instructed that ocular products, if handled 
improperly, can become contaminated by common bacteria known to cause ocular 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result 
from using contaminated products (see <span><a href="#section-"> PRECAUTIONS: General</a></span>).</p>
<p>If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> 
develops, the patient should be advised to stop use and consult a physician. Do 
not use this product if you are allergic to any of the listed ingredients.</p>
<p>Keep tightly closed when not in use. Keep out of reach of children.</p>
<a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Long-term studies in animals to evaluate carcinogenic or 
mutagenic potential have not been conducted with polymyxin B sulfate. Treatment 
of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro </span>with neomycin 
increased the frequency of chromosome aberrations at the highest concentrations 
(80 ug/mL) tested; however, the effects of neomycin on carcinogenesis and 
mutagenesis in humans are unknown.</p>
<p>Long-term studies in animals (rats, rabbits, mice) showed no evidence of 
carcinogenicity or mutagenicity attributable to oral administration of 
corticosteroids. Long-term animal studies have not been performed to evaluate 
the carcinogenic potential of topical corticosteroids. Studies to determine 
mutagenicity with hydrocortisone have revealed negative results. Use of 
corticosteroid medication in the treatment of herpes simplex requires great 
caution. Polymyxin B has been reported to impair the motility of equine sperm, 
but its effects on male or female fertility are unknown. Long-term animal 
studies have not been performed to evaluate the effect on fertility of topical 
corticosteroids.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy<p><span class="Italics">Teratogenic Effects: </span>Pregnancy 
Category C. Corticosteroids have been found to be teratogenic in rabbits when 
applied topically at concentrations of 0.5% on days 6 -18 of gestation and in 
mice when applied topically at a concentration of 15% on days 10 -13 of 
gestation. There are no adequate and well-controlled studies in pregnant women. 
Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension 
should be used during pregnancy only if the potential benefit justifies the 
potential risk to the fetus.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Nursing Mothers<p>It is not known whether topical administration of corticosteroids 
could result in sufficient systemic absorption to produce detectable quantities 
in human milk. Systemically administered corticosteroids appear in human milk 
and could suppress growth, interfere with endogenous corticosteroid production, 
or cause other untoward effects. Because of the potential for serious adverse 
reactions in nursing infants from Neomycin and Polymyxin B Sulfates and 
Hydrocortisone Ophthalmic Suspension, a decision should be made whether to 
discontinue nursing or to discontinue the drug, taking into account the 
importance of the drug to the mother.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in pediatric patients have not been 
established.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Geriatric Use<p>No overall differences in safety or effectiveness have been 
observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<a href="http://"></a>ADVERSE REACTIONS<p class="First">Adverse reactions have occurred with 
corticosteroid/anti-infective combination drugs which can be attributed to the 
corticosteroid component, the anti-infective component, or the combination. The 
exact incidence is not known.</p>
<p>Reactions occurring most often from the presence of the anti-infective 
ingredient are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and 
conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <span><a href="#splSectionWarnings">WARNINGS</a></span>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> 
reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely.</p>
<p>The reactions due to the corticosteroid component in decreasing order of 
frequency are: elevation of intraocular pressure (IOP) with possible development 
of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> 
formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span>: </span>The development of secondary 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has occurred after use of combinations containing corticosteroids and 
antimicrobials. Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone 
to develop coincidentally with long-term applications of corticosteroid. The 
possibility of fungal invasion must be considered in any persistent corneal 
ulceration where corticosteroid treatment has been used. </p>
<p>Local irritation on instillation has been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<a href="http://"></a>DOSAGE AND ADMINISTRATION<p class="First">One or two drops in the affected eye every 3 or 4 hours, 
depending on the severity of the condition. The suspension may be used more 
frequently if necessary.</p>
<p>Not more than 20 mL should be prescribed initially and the prescription 
should not be refilled without further evaluation as outlined in PRECAUTIONS 
above.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<a href="http://"></a>HOW SUPPLIED<p class="First">Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic 
Suspension is available in a DROP-TAINER* bottle containing 7.5 mL. NDC 
61314-641-75</p>
<p><span class="Bold">SHAKE WELL BEFORE USING.</span></p>
<p>Store at 20°-25°C (68°-77°F).</p>
<p><span class="Bold">Rx Only</span></p>
<p>*DROP-TAINER is a Registered trademark of Alcon Manufacturing Ltd.</p>
<p><span class="Bold">9002784-0707</span></p>
<p>Mfd. For:</p>
<p><span class="Bold">FALCON Pharmaceuticals, Ltd.</span></p>
<p>For t Worth, Texas 76134 USA</p>
<p>Mfd. By:</p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>Fort Worth, Texas 76134 USA</p>
<p>Printed in USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<p class="First"><img alt="NEO-POLY-B 3-5MG-10KU LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64e4cb91-f5bd-4a2f-b92d-0a1341f40d35&amp;name=NEO-POLY-B%203-5MG-10KU%20LABEL.jpg">     NEO-POLY-B 3-5MG-10KU LABEL IMAGE<br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate and hydrocortisone suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-347(NDC:61314-641)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN SULFATE</td>
<td class="formItem">3.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B SULFATE</td>
<td class="formItem">10000 [USP'U]  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>THIMEROSAL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-347-75</td>
<td class="formItem">7.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062423</td>
<td class="formItem">08/25/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7b0183bf-d621-4f73-9ee1-0729b4731cfe</div>
<div>Set id: 64e4cb91-f5bd-4a2f-b92d-0a1341f40d35</div>
<div>Version: 1</div>
<div>Effective Time: 20100609</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
